Literature DB >> 24797365

Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation.

Hilary F Armstrong1, P Christian Schulze, Matthew Bacchetta, Wilawan Thirapatarapong, Matthew N Bartels.   

Abstract

BACKGROUND AND
OBJECTIVE: Pulmonary hypertension (PH) is a known complication in patients with interstitial lung disease (ILD). Cardiopulmonary exercise testing (CPET) is an essential tool for the assessment of patients with cardiac and pulmonary diseases due to its prognostic and therapeutic implications. Few studies have evaluated the relationship between CPET response and mean pulmonary artery pressures (mPAP) in ILD. The purpose of the present study was to determine and compare the potential correlations between CPET, 6-min walk test (6MWT), pulmonary function testing (PFT) and PH in patients with ILD being evaluated for lung transplantation.
METHODS: The present study reviewed patients with ILD who received lung transplantations and had CPETs within 2 years before transplantation, right heart catheterizations, PFTs and 6MWTs within 4 months of CPET.
RESULTS: A total of 72 patients with ILD were analysed; 36% had PH. There were significant correlations between mPAP and CPET parameters in patients with PH; but mPAP had no impact on percent of predicted diffusion capacity of the lung for carbon monoxide or 6-min walk distance (6MWD). CPET parameters were able to detect differences between levels of severity of PH through the use of the ratio of minute ventilation to rate of carbon dioxide production (VE/VCO2) and the partial pressure of end-tidal carbon dioxide.
CONCLUSIONS: This is the first study that analyses 6MWD, PFT and CPET in patients with ILD awaiting lung transplantation with and without PH. The present study demonstrates the significant impact of PH on exercise capacity and performance in patients with ILD awaiting lung transplantation.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  cardiopulmonary exercise test; interstitial lung disease; lung transplantation; pulmonary hypertension; respiratory insufficiency

Mesh:

Substances:

Year:  2014        PMID: 24797365      PMCID: PMC4065213          DOI: 10.1111/resp.12306

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  32 in total

1.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  Christopher J Lettieri; Steven D Nathan; Scott D Barnett; Shahzad Ahmad; Andrew F Shorr
Journal:  Chest       Date:  2006-03       Impact factor: 9.410

2.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease.

Authors:  Hanno H Leuchte; Rainer A Baumgartner; Michal El Nounou; Michael Vogeser; Claus Neurohr; Michael Trautnitz; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2006-01-13       Impact factor: 21.405

Review 3.  Diagnosis and assessment of pulmonary arterial hypertension.

Authors:  David B Badesch; Hunter C Champion; Miguel Angel Gomez Sanchez; Marius M Hoeper; James E Loyd; Alessandra Manes; Michael McGoon; Robert Naeije; Horst Olschewski; Ronald J Oudiz; Adam Torbicki
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

4.  Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review.

Authors:  Ross Arena; Carl J Lavie; Richard V Milani; Jonathan Myers; Marco Guazzi
Journal:  J Heart Lung Transplant       Date:  2009-12-06       Impact factor: 10.247

5.  Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis.

Authors:  Sven Gläser; Oliver Noga; Beate Koch; Christian F Opitz; Bernd Schmidt; Bettina Temmesfeld; Marcus Dörr; Ralf Ewert; Christoph Schäper
Journal:  Respir Med       Date:  2008-09-18       Impact factor: 3.415

6.  Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.

Authors:  Tomohiro Handa; Sonoko Nagai; Shinji Miki; Yasutaka Fushimi; Kosuke Ohta; Michiaki Mishima; Takateru Izumi
Journal:  Chest       Date:  2006-05       Impact factor: 9.410

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 8.  Pulmonary hypertension in interstitial lung disease.

Authors:  J Behr; J H Ryu
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

9.  Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant.

Authors:  A F Shorr; J L Wainright; C S Cors; C J Lettieri; S D Nathan
Journal:  Eur Respir J       Date:  2007-07-11       Impact factor: 16.671

Review 10.  Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

Authors:  Marius M Hoeper; Joan Albert Barberà; Richard N Channick; Paul M Hassoun; Irene M Lang; Alessandra Manes; Fernando J Martinez; Robert Naeije; Horst Olschewski; Joanna Pepke-Zaba; Margaret M Redfield; Ivan M Robbins; Rogério Souza; Adam Torbicki; Michael McGoon
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  8 in total

1.  Frailty and maximal exercise capacity in adult lung transplant candidates.

Authors:  Aimee M Layton; Hilary F Armstrong; Matthew R Baldwin; Anna J Podolanczuk; Nicole M Pieszchata; Jonathan P Singer; Selim M Arcasoy; Kimberly S Meza; Frank D'Ovidio; David J Lederer
Journal:  Respir Med       Date:  2017-08-10       Impact factor: 3.415

2.  Correlation Between N-Terminal Pro-Brain Natriuretic Peptide Levels and Cardiopulmonary Exercise Testing in Patients With Pre-Capillary Pulmonary Hypertension: A Pilot Study.

Authors:  Sahachat Aueyingsak; Wilaiwan Khrisanapant; Upa Kukongviriyapun; Orapin Pasurivong; Pailin Ratanawatkul; Chinadol Wanitpongpan; Burabha Pussadhamma
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2020-10-13

3.  Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease.

Authors:  Rudolf K F Oliveira; Aaron B Waxman; Paul J Hoover; Paul F Dellaripa; David M Systrom
Journal:  Chest       Date:  2020-03-12       Impact factor: 9.410

4.  Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience.

Authors:  Chi Young Kim; Ji Eun Park; Ah Young Leem; Joo Han Song; Song Yee Kim; Kyung Soo Chung; Eun Young Kim; Ji Ye Jung; Young Ae Kang; Young Sam Kim; Joon Chang; Jin Gu Lee; Hyo Chae Paik; Moo Suk Park
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Mechanisms of exercise limitation in patients with chronic hypersensitivity pneumonitis.

Authors:  Olívia Meira Dias; Bruno Guedes Baldi; Jeferson George Ferreira; Letícia Zumpano Cardenas; Francesca Pennati; Caterina Salito; Carlos Roberto Ribeiro Carvalho; Andrea Aliverti; André Luis Pereira de Albuquerque
Journal:  ERJ Open Res       Date:  2018-08-22

6.  Lung function in relation to six-minute walk test in pulmonary hypertension.

Authors:  Amir Farkhooy; Michaela Bellocchia; Hans Hedenström; Daniela Libertucci; Caterina Bucca; Christer Janson; Paolo Solidoro; Andrei Malinovschi
Journal:  Eur Clin Respir J       Date:  2020-04-07

Review 7.  Pulmonary hypertension complicating pulmonary sarcoidosis.

Authors:  M P Huitema; J C Grutters; B J W M Rensing; H J Reesink; M C Post
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380

8.  Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Can Respir J       Date:  2016-05-18       Impact factor: 2.409

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.